D with metabolic probes that could be tested with caution in the clinical development of this agent using PET imaging.Material and methodsReagents and cell linesNRASBRAF R BRAF-RBRAF S BRAF-SFigure 4 Metabolic tracer uptake profile upon exposure to TAK733. The same six melanoma cell lines from Figure 2 representing the spectrum of sensitivities for NRAS and BRAF mutant cells were exposed to TAK733